Navigation Links
U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Date:11/20/2007

ADTs, including selective serotonin reuptake inhibitors (SSRIs): Lexapro(R) (escitalopram), Prozac(R) (fluoxetine), Paxil CR(R) (paroxetine controlled-release), Zoloft(R) (sertraline); or a serotonin-norepinephrine reuptake inhibitor (SNRI): Effexor XR(R) (venlafaxine extended release). The dosage range for adjunctive ABILIFY was 2-20 mg/day (15 mg/day was the maximum dose for patients receiving ABILIFY as an adjunct to Paxil CR or Prozac).

The primary efficacy endpoint was the mean change from baseline -- the end of the prospective treatment phase -- to the end of the randomized treatment phase in a standard measure called Montgomery-Asberg Depression Rating Scale (MADRS), a 10-item clinician-rated scale used to assess depressive symptoms. A reduction in MADRS Total Score represents an improvement in depressive symptoms. The key secondary endpoint was the Sheehan Disability Scale (SDS), a three-item self-rated instrument used to assess the impact of depression on three domains of functioning (work/school, social life and family life) with each item scored from zero (not at all) to 10 (extreme). Safety evaluations included incidence of adverse reactions, discontinuation rate due to adverse reactions and laboratory measures.

For the primary endpoint, both studies showed that taking ABILIFY plus an ADT provided superior improvement in depressive symptoms to ADT alone at study endpoint (week six), as measured by the reduction of the MADRS Total Scores.(3) For the secondary endpoint, ABILIFY plus an ADT was also superior to placebo plus ADT in reducing the mean SDS Total Score in one study.

In these studies, adjunctive ABILIFY demonstrated no clinically important differences on metabolic parameters, including prolactin, fasting glucose, HDL, LDL and total cholesterol. The median percent change from baseline in triglycerides was 5 percent for adjunctive ABILIFY-treated patients vs 0 percent for adjunctive placebo-treated patients. In the studies, weight
'/>"/>

SOURCE Bristol-Myers Squibb Company and Otsuka PharmaceuticalCo., Ltd.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Baxter and Halozyme Announce Collaboration for Development of Subcutaneous GAMMAGARD LIQUID(TM) Administration Using Enhanze(TM) Technology
2. Bioscrypts V-Station MIFARE Placed on Transportation Security Administrations Qualified Products List
3. Australian Therapeutics Goods Administration Approval for ActiPatch Achieved
4. FDA Approves Administration of LEXIVA(R) with Lower Dose of Boosting Medication Ritonavir
5. Korean Food and Drug Administration Approval for ActiPatch Achieved
6. Brazilian National Biosafety Technical Committee Approves Monsanto Company Insect-Protected Corn Trait
7. FDA Approves RISPERDAL(R) to Treat Adolescents with Schizophrenia and Children and Adolescents with Bipolar Mania
8. FDA Approves ACAM2000(TM) Vaccine for Protection Against Smallpox
9. NJ Board of Pharmacy Approves Wedgewood Pharmacy Technician-Training Program
10. FDA Approves Expanded Labeling for Campath(R) to Include First-line Treatment for Leading Form of Adult Leukemia
11. FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2009)... DIEGO, Dec. 11 Ambit Biosciences Corporation announced ... Texas M. D. Anderson Cancer Center of the first ... Monotherapy E fficacy) Phase 2 pivotal ... leukemia (AML). AC220 is a novel, orally available, ... designed as a FMS-like tyrosine kinase-3 (FLT3) inhibitor. ...
(Date:12/11/2009)... 11 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ: ... the appointment of Dr. Alan Warrander to the ... Business Development. ,, "Dr. Warrander will be responsible ... for REOLYSIN(R)," said Dr. Brad Thompson, President and ... the design of a Phase 3 trial examining ...
(Date:12/10/2009)... 10 Endologix, Inc. (Nasdaq: ELGX ... disorders, announced today that Dan Lemaitre, former President ... Board of Directors effective December 11, 2009. ... non-independent directors. ,, Franklin D. Brown, Chairman of ... Dan Lemaitre to the Endologix Board of Directors. ...
(Date:12/10/2009)... ON, Dec. 10 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... life sciences product development company that identifies and ... at various stages of development, today provided an ... in the merger of Cytopia Ltd. into YM, ... 2009. The board of directors of Cytopia has ...
Breaking Biology Technology:Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 2Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 3Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 4Ambit Biosciences Initiates First Phase 2 Clinical Trial of AC220 in Acute Myeloid Leukemia 5Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 2Oncolytics Biotech(R) Inc. Appoints Senior Vice President, Global Licensing and Business Development 3Endologix Appoints Dan Lemaitre to its Board of Directors 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 2YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 3YM BIOSCIENCES OFFER FOR CYTOPIA APPROVED TO PROCEED TO SHAREHOLDER VOTE BY AUSTRALIAN COURT 4
... the Board -, MADISON, N.J., April 24 ... Robert Essner, 60, has decided to retire,from the Company ... position,of Chairman since January 2003 and served as Wyeth,s ... of Directors has elected,Bernard Poussot, Wyeth,s President and Chief ...
... N.J., April 24 Pharmasset, Inc.,(Nasdaq: VRUS ) ... Conference being held from April 30, 2008 to May ... Schaefer Price,Pharmasset,s Chief Executive Officer, will provide an overview ... Morgan Stanley,representatives on Wednesday, April 30, 2008 at 3:40 ...
... genetics,Inc. (Nasdaq: DCGN ) today announced that it will ... to be issued on Thursday, May 1,after the close of ... live,webcast of its conference call to discuss these results and ... noon GMT/1pm,British Summer Time., The webcast can be accessed ...
Other Biology Technology:Wyeth Chairman Robert Essner Announces June 27 Retirement 2Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th 2deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results 2
(Date:12/13/2009)... discovered five genetic variants that are associated with the ... international consortium of 96 scientists from 63 centres in ... basis of lung diseases. , The new findings provide ... Obstructive Pulmonary Disease (COPD) and asthma. In the past ... the molecular pathways that affect the health of the ...
(Date:12/11/2009)... COLLINS, COWild Malus orientalis species of wild apples ... native to the Middle East and Central Asia. A ... M. orientalis varieties from Georgia and Armenia with ... the large population and establishes a core collection that ... the breeding and research communities. , To identify and ...
(Date:12/11/2009)... CLEVELAND Case Western Reserve University has granted ... Inc. regarding a portfolio of insulin analogs. The ... exercise its option to obtain an exclusive license ... , Cleveland-based Thermalin Diabetes is developing treatments that ... the $12 billion, rapidly growing insulin market. Insulin ...
Breaking Biology News(10 mins):New genes for lung disease discovered 2Understanding apples' ancestors 2Case Western Reserve University grants option to startup Thermalin Diabetes Inc. 2Neural stem cell differentiation factor discovered 9064 1Neural stem cell differentiation factor discovered 9064 2First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 1First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 2First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 3First Human Receives Cardiac Stem Cells in Clinical Trial to Heal Damage Caused By Heart Attacks 50395 4Allegiant Professional Business Services Inc Signs New Members to Its PPO Health Insurance Plan Annual Revenues Projected to Increase by 245M 50391 1Allegiant Professional Business Services Inc Signs New Members to Its PPO Health Insurance Plan Annual Revenues Projected to Increase by 245M 50391 2
... The American Dietetic Association has released an updated ... enhanced foods can benefit a person,s health when consumed ... and urges continued efforts to educate the public on ... issue of the Journal of the American Dietetic ...
... MD, PhD is the inaugural recipient of the Richard King ... American College of Medical Genetics Foundation (ACMGF) to encourage ABMG ... quality research in Genetics in Medicine. Each year the editorial ... ABMG trainee who was either a first or corresponding author ...
... H. Holmes Pioneer Awards will be presented on April 3 ... The awards honor two recipients who have contributed to the ... will be presented to Lawrence Platt, MD, of the David ... Los Angeles, California. The basic science award will be presented ...
Other Biology News:ADA releases updated position statement on functional foods 2ADA releases updated position statement on functional foods 3Jonathan Berg, M.D., Ph.D. awarded Richard King Trainee Award for Best in Genetics in Medicine 2AIUM Presents 2009 Joseph H. Holmes Pioneer Awards 2
Recombinant Viral CCI/Fc Chimera, CF...
GENOMIPHI V2 DNA AMP KIT 25RXN, 1 EA. Category: Genomics DNA Amplification....
... precipitation offers major advantages over other RNA precipitation ... protein or carbohydrates. It is the method of ... synthesis from RNA preparations. Note, LiCl precipitation may ... isolations. If the RNA is to be used ...
... The SlowFade Light Antifade Kit is ... photobleaching seen with fluorescent dyes. This formulation ... fluorescein AMCA and Cascade Blue fluorophores that ... (S-2828). This kit is available with the ...
Biology Products: